Eli Lilly will acquire Kelonia Therapeutics in a deal worth up to $7 billion, expanding its push into cancer treatments. Kelonia shareholders will receive $3.25 billion upfront in cash, with additional milestone-based payments. The deal gives Lilly access to Kelonia’s experimental in vivo CAR-T therapy for blood cancers, and is expected to close in the second half of 2026.
Eli Lilly to Acquire Kelonia Therapeutics in Up to $7B Cancer Drug Deal
